Statement of Need
Lung cancer is the leading cause of cancer death in the United States and accounted for an estimated 161,840 deaths in 2008. Despite several decades of extensive research, the median survival for patients with non-small cell lung cancer (NSCLC) is approximately 1 year. Seventy percent of patients diagnosed with NSCLC have locally advanced or metastatic disease. Although multiple studies have confirmed the efficacy of platinum doublets for the treatment of advanced or metastatic NSCLC, a plateau in treatment efficacy seems to have been reached. In an effort to increase efficacy and reduce treatment-related toxicities, investigators have focused on developing strategies that involve molecular considerations for patient selection in the early and advanced stage treatment settings. The identification of biomarkers that predict response to chemotherapy and targeted therapy has the potential to transform the treatment paradigm of NSCLC from one that relies on clinical characteristics, such as tumor stage, performance status, and smoking history, to one where the analysis of molecular characteristics of individual patients is used for therapeutic decision making. At the end of this activity, participants will be able to evaluate data from recent clinical trials that are investigating molecular biomarkers as potential predictors of response or resistance to chemotherapeutic and targeted therapies for patients with NSCLC.
Target Audience
This activity is intended for medical oncologists, thoracic surgeons, nurses, pharmacists, physician assistants, and other healthcare professionals interested in the treatment of patients with NSCLC.
Educational Objectives
On completion of this activity, participants will be able to: 1. Describe the rationale for using molecular markers to individualize treatment for patients with NSCLC. 2. Evaluate the use of molecular profiling to predict clinical outcomes in the adjuvant setting for patients with NSCLC. 3. Discuss the use of predictive markers to direct selection of chemotherapeutic agents for the treatment of NSCLC. 4. Discuss the use of molecular markers to refine the use of targeted agents for the treatment of NSCLC. 5. Describe data supporting the use of clinical prognostic and predictive factors for patients with NSCLC receiving targeted therapies.
Method of Participation
Successful completion of this continuing education activity includes reviewing the target audience, educational objectives, and author disclosures, as well as reading the course materials in their entirety.
Accreditation
Physicians : The Center for Biomedical Continuing Education (CBCE™) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The CBCE designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.25 hours of Category 1 credit for completing this program.
Nurses: The CBCE™ is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
The CBCE designates this educational activity for 1.25 contact hours.
Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.
Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. CPE Credit: 1.25 contact hours or 0.125 CEUs Universal Program Number: 195-000-09-016-H01-P
Credit Instructions
Successful completion of this activity requires the following:
• Read the journal supplement.
• Score 70% or above on the posttest.
• Complete the Evaluation and Request for Credit Form.
• Submit the completed posttest and form to the CBCE following the activity to receive credit.
Certificate
Participants will receive their certificate 4-6 weeks after the CBCE receives their posttest and form.
Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE, Genentech BioOncology/OSI Pharmaceuticals, Inc.; Lilly USA, LLC; Pfizer Oncology; or sanofi-aventis. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians' Desk Reference.
Disclosure of Financial Relationships With Any Commercial Interest
As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone who is in a position to control the content of an educational activity discloses all relevant financial relationships with any commercial interest, and identifies and resolves all conflicts of interest before the educational activity. The CBCE defines "relevant financial relationships" as any amount occurring within the past 12 months.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honorarium, ownership interest (eg, stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The CBCE considers relationships of the person involved in the educational activity to include financial relationships of a spouse or partner.
Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.
Disclosure of Potential Conflicts of Interest
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. The identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education.
